Advertisement

Degradation Kinetics by MAO of PEA Derivatives. A Model for the Molecular Basis of their Analgesic and Behavioral Effects?

  • A. D. Mosnaim
  • M. E. Wolf
  • E. A. Zeller

Abstract

The classical endogenous noncatecholic phenylethylamines, phenylethylamine (PEA), phenylethanolamine, p-tyramine and p-octopamine appear to be involved in peripheral and central nervous system synaptic transmission mechanisms (1,2). The physiological and pharmacological actions of PEA appear of particular importance as alterations in the metabolism of this amine has been postulated to contribute to the pathophysiology of a number of neuropsychiatric disorders (3–7), migraine (8,9) and diabetes (10). In order to better understand the molecular basis of PEA actions we have examined the relationship between the chemical structure, the analgesic activity and kinetic parameters of degradation by monoamine oxidase (MAO) of a series of monosubstituted derivatives of PEA.

Keywords

Monoamine Oxidase Degradation Kinetic Monosubstituted Derivative Platelet Monoamine Oxidase Shriner Hospital 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mosnaim A. D. and Wolf M. E. (eds.) (1978) Non-catecholic Phenylethylamines, Part I:Phenylethylamine; Biological Mechanisms and Clinical Aspects. Marcel Dekker, New York.Google Scholar
  2. 2.
    Mosnaim A. D. and Wolf M. E. (eds.) (1980) Non-catecholic Phenylethylamines, Part 2: Phenylethanolamine, Tyramines and Octopamine. Marcel Dekker, New York.Google Scholar
  3. 3.
    Mosnaim A. D., Inwang E. E., Sugerman J. H., DeMartini W., and Sabelli H. C. (1973) Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression. Biol. Psychiat. 6, 235–257.PubMedGoogle Scholar
  4. 4.
    Sabelli H. C. and Mosnaim A. D. (1974) Phenylethylamine hypothesis of affective behavior. Am. J. Psychiat. 131, 695–699.PubMedGoogle Scholar
  5. 5.
    Sandler M. and Reynolds G. P. (1976) Does phenylethylamine cause schizophrenia? Lancet 1, 70–71.PubMedCrossRefGoogle Scholar
  6. 6.
    Karoum F., Linniola M., Potter W. Z., Chuang L.-W., Goodwin F. K., and Wyatt R. J. (1982) Fluctuating high urinary phenylethylamine excretion rates in some bipolar affective disorder patients. Psychiat. Res. 6, 215–222.CrossRefGoogle Scholar
  7. 7.
    Wolf M. E. and Mosnaim A. D. (1983) Phenylethylamine in neuropsychiatric disorders. Gen. Pharmacol. 14, 385–390.PubMedCrossRefGoogle Scholar
  8. 8.
    Diamond S., Dalessio D., Graham J., and Medina J. L. (eds.) (1975) Vasoactive Substances Relevant to Migraine. Charles C. Thomas, New York.Google Scholar
  9. 9.
    Mosnaim A. D., Wine R., Karoum F., Diamond S. and Wolf M. E. (1982) Methionine enkephalin, phenylethylamine, phenylacetic acid, platelet monoamine oxidase, and prolactin in plasma of migraine patients. Clinical Pharmac. and Therap. 31, 251–252.Google Scholar
  10. 10.
    Mosnaim A. D., Karoum F., Zeller A., Callaghan O. H., Singh S. P., and Wolf M. E. (1982) Platelet monoamine oxidase activity and plasma levels of non-catecholic phenylethy1amines in insulin-dependent diabetic subjects. Clin. Chim. Acta 126, 237–242.PubMedCrossRefGoogle Scholar
  11. 11.
    Zeller E. A., Mosnaim A. D., Borison R. L., and Huprikar S. V. (1976) Phenylethylamine: Studies on the mechanism of its physiological action, in Advances in Biochemical Psychopharmacology, Vol. 15: First and Second Messengers—New Vistas, pp. 75–86. Raven Press, New York.Google Scholar
  12. 12.
    Kochli H. and von Wartburg J. P. (1978) A sensitive photometric assay for monoamine oxidase. Anal. Biochem. 84, 127–135.PubMedCrossRefGoogle Scholar
  13. 13.
    Ehrenpreis S., Balagot R. C., Comaty J. E., and Myles S. B. (1979) Advances in Pain Research and Therapy, Vol. 3, pp. 479–488. Raven Press, New York.Google Scholar
  14. 14.
    Ungar F., Mosnaim A, D., Ungar B., and Wolf M. E. (1978) Preliminary studies of the sodium borohydride stabilizable binding of phenylethylamine and tyramine to brain preparation. Res. Commun. Chem. Pathol. Pharmacol. 19, 427–434.PubMedGoogle Scholar
  15. 15.
    Hansen T. R., Greenberg J., and Mosnaim A. D. (1980) Direct effect of phenylethylamine upon isolated rat aortic strip. Eur. J. Pharmacol. 63, 95–101.PubMedCrossRefGoogle Scholar
  16. 16.
    Mosnaim A. D., Vazquez A., and Nair V. (1982) First World Congress on Toxicology and Environmental Health, Washington, D. C. (Abst.).Google Scholar
  17. 17.
    Jackson D. M. and Smythe D. B. (1973) The distribution of β–phenylethylamine in discrete regions of the rat brain and its effect on brain noradrenaline, dopamine and 5-hydroxytryptamine levels. Neuropharmacology 12, 663–668.PubMedCrossRefGoogle Scholar
  18. 18.
    Sabelli H. C., Vazquez A. J., Mosnaim A. D., and Madrid-Pedemonte L. (1974) 2-Phenylethylamine as a possible mediator for Δ9-tetrahydrocannabinol-induced stimulation. Nature 248, 144–145.PubMedCrossRefGoogle Scholar
  19. 19.
    Borison R. L., Havdala H. S., and Diamond B. I. (1977) Chronic phenylethylamine-induced stereotypy in rats: A new animal model for schizophrenia? Life Sci. 21, 117–122.PubMedCrossRefGoogle Scholar
  20. 20.
    Dourish C. T. (1982) A pharmacological analysis of the hyperactivity syndrome induced by 3-phenylethylamine in the mouse. Br. J. Pharmac. 77, 129–139.Google Scholar
  21. 21.
    Sloviter R. S., Connor J. D., and Drust E. G. (1980) Serotonergic properties of 3-phenylethylamine in rats. Neuropharmacology 19, 1071–1074.PubMedCrossRefGoogle Scholar
  22. 22.
    Goudie A. J. and Buckland C. (1982) Serotonin receptor blockade potentiates the behavioral effects of β-phenylethylamine. Neuropharmacology 21, 1267–1272.PubMedCrossRefGoogle Scholar
  23. 23.
    Garzon J., Moratalla R., and Del Rio J. (1980) Potentiation of the analgesia induced in rats by morphine or [D-Ala2]-Metenkephalinamide after inhibition of brain type B monoamine oxidase: The role of phenylethylamine. Neuropharmacology 19, 723–729.PubMedCrossRefGoogle Scholar

Copyright information

© The Humana Press Inc. 1984

Authors and Affiliations

  • A. D. Mosnaim
    • 1
  • M. E. Wolf
    • 1
  • E. A. Zeller
    • 1
  1. 1.Chicago Med.School & Shriners HospitalUSA

Personalised recommendations